Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day
versus placebo in the treatment of patients with primary progressive multiple sclerosis or
relapse-free secondary progressive multiple sclerosis.